未知生产厂商
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Neisseria meningitidis is a human-encapsulated Gram-negative diplococcus that is known to cause serious and life-threatening invasive disease. N. meningitidis has several different serogroups that are classified based on the composition of capsular polysaccharide (CPS) polymers. Among the serogroups, serogroups A, B, C, W, Y, and X account for the majority of meningococcal diseases. Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains bacterial CPS (serogroup A, C, Y, and W-135 oligosaccharides) conjugated to a carrier protein (CRM), allowing more robust antibody responses compared to plain polysaccharide vaccines. Upon administration, this conjugate vaccine promotes the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135 in vaccinated individuals.
This is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine does not prevent N. meningitidis serogroup B infections.
共 4 项相关疾病
